Immutep stumbles on into phase 3
Predictably Tacti-003 fails, but funding is secured – from investors, not a partner.
Merck’s big ADC deal takes a blow
A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.
Bristol overtakes Amgen in colorectal
Meanwhile, Bristol’s other competition in this disease looks set to come from China.
Merck seeks the next Keytruda
The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.
Toxicity hits BioNTech’s MediLink tie-up
A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?
Endometrial cancer becomes a three-horse race
Imfinzi scores an unexpected approval based on a post-hoc subgroup analysis.
ASCO 2024 – Krazati looks more similar than different to Lumakras
Meanwhile, Lilly gets in on the next-gen KRAS action.
